1Department of Clinical Pharmacy, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
2Social Development and Health Promotion Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
3Department of Anesthesia, School of Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
Copyright © 2022 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTIONS
Conceptualization: FH, HK, FS. Data curation: SK, FH, FS. Formal analysis: SK, FH, FS. Methodology: all authors. Project administration: HK, FS. Visualization: FH, HK, FS. Writing–original draft: all authors. Writing–review & editing: all authors.
Variable | No. (%) |
---|---|
No past medical history | 19 (20.00) |
HTN | 19 (20.00) |
Solid tumor | 12 (12.63) |
HTN+DM | 8 (8.42) |
Other | 37 (38.94) |
Variable | Value |
---|---|
Age (yr) | 63.11±17.58 |
Male | 63/95 (66.3) |
Serum creatinine (mg/dl) | 1.06±0.30 |
SOFA score | 8.09±3.52 |
APACHE II score | 20.09±7.52 |
Charlson comorbidity index | 3.69±2.16 |
Body surface area | 1.83±0.14 |
Body mass index (kg/m2) | 25.24±3.40 |
Ideal body weight (kg) | 64.37±7.00 |
AKI stage | |
Stage 1 | 74 (77.89) |
Stage 2 | 14 (14.73) |
Stage 3 | 7 (7.36) |
Variable | No. (%) |
---|---|
No past medical history | 19 (20.00) |
HTN | 19 (20.00) |
Solid tumor | 12 (12.63) |
HTN+DM | 8 (8.42) |
Other | 37 (38.94) |
Formula | Mean GFR | Correlation coefficient | P-value |
---|---|---|---|
Modified CG | 38.97±17.16 | 0.30 | 0.006 |
MDRD | 40.37±17.53 | 0.24 | 0.031 |
CKD-EPI | 37.49±17.61 | 0.27 | 0.015 |
Kinetic-GFR | 33.85±17.45 | 0.29 | 0.008 |
Brater | 58.94±25.33 | 0.41 | 0.010 |
Chiou | 40.19±20.67 | 0.26 | 0.018 |
CG | 41.51±17.31 | 0.26 | 0.018 |
Jelliffe | 36.43±18.97 | 0.32 | 0.001 |
Formula | Stage |
||
---|---|---|---|
1 | 2 | 3 | |
Modified CG | 0.24 | 0.53 | –0.03 |
MDRD | 0.17 | 0.07 | 0.03 |
CKD-EPI | 0.20 | 0.29 | 0.00 |
Kinetic-GFR | 0.17 | 0.76 | 0.37 |
Brater | 0.23 | 0.51 | 0.18 |
Chiou | 0.26 | 0.26 | 0.03 |
CG | 0.19 | 0.23 | 0.10 |
Jelliffe | 0.25 | 0.51 | 0.37 |
Antibiotic | Frequency (n=95) | Underdosed | Optimum | overdosed |
---|---|---|---|---|
Vancomycin | 52 | 10 | 25 | 17 |
Meropenem | 43 | 1 | 25 | 17 |
Piperacillin-tazobactam | 25 | 4 | 17 | 4 |
Levofloxacin | 24 | 1 | 15 | 8 |
Imipenem/cilastatin | 8 | 1 | 4 | 3 |
Ampicillin/sulbactam | 6 | 1 | 3 | 3 |
Colistin | 5 | 1 | 2 | 2 |
Values are presented as mean±standard deviation or number (%). SOFA: Sequential Organ Failure Assessment; APACHE: Acute Physiology and Chronic Health Evaluation; AKI: Acute Kidney Injury.
HTN: hypertension; DM: diabetes mellitus.
Values are presented as mean±standard deviation. GFR: glomerular filtration rate; CG: Cockcroft-Gault; MDRD: modification of diet in renal disease; CKD-EPI: chronic kidney disease-epidemiology collaboration.
AKI: acute kidney injury; CG: Cockcroft-Gault; MDRD: modification of diet in renal disease; CKD-EPI: chronic kidney disease-epidemiology collaboration; GFR: glomerular filtration rate.